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Abstract
Recent studies have suggested the potential of probiotic organisms to be adapted for the synthesis and delivery of oral
therapeutics. The probiotic yeast Saccharomyces boulardii would be especially well suited for this purpose due to its ability,
in contrast to probiotic prokaryotes, to perform eukaryotic post translational modifications. This probiotic yeast thus has the
potential to express a broad array of therapeutic proteins. Currently, however, use of wild type (WT) S. boulardii relies on
antibiotic resistance for the selection of transformed yeast. Here we report the creation of auxotrophic mutant strains of S.
boulardii that can be selected without antibiotics and demonstrate that these yeast can express functional recombinant
protein even when recovered from gastrointestinal immune tissues in mice. A UV mutagenesis approach was employed to
generate three uracil auxotrophic S. boulardii mutants that show a low rate of reversion to wild type growth. These mutants
can express recombinant protein and are resistant in vitro to low pH, bile acid salts, and anaerobic conditions. Critically, oral
gavage experiments using C57BL/6 mice demonstrate that mutant S. boulardii survive and are taken up into gastrointestinal
immune tissues on a similar level as WT S. boulardii. Mutant yeast recovered from gastrointestinal immune tissues
furthermore retain expression of functional recombinant protein. These data show that auxotrophic mutant S. boulardii can
safely express recombinant protein without antibiotic selection and can deliver recombinant protein to gastrointestinal
immune tissues. These auxotrophic mutants of S. boulardii pave the way for future experiments to test the ability of S.
boulardii to deliver therapeutics and mediate protection against gastrointestinal disorders.
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Introduction
Saccharomyces cerevisiae subspecies boulardii is a generally
recognized as safe (GRAS) yeast strain classified as a subspecies of
the well characterized laboratory yeast S. cerevisiae [1,2]. S.
boulardii is currently used as a probiotic to treat antibiotic-induced
diarrhea in children and adults, recurrent Clostridium difficile
infections, inflammatory bowel disease, and other gastrointestinal
disorders [3,4]. The exact mechanisms by which S. boulardii
mediates these protective effects are not fully understood.
However, administration of S. boulardii in animal models has
been shown to increase secretory IgA, interleukin 10 (IL-10), and
IL-10 induced T regulatory cells [5,6] as well as to preserve
intestinal epithelial integrity in colitis models [7–9] and to degrade
specific pathogen toxins [10,11].
Key features of S. boulardii have raised the interesting prospect
of using this probiotic yeast not only as a preparation of wild type
cells for the treatment of gastrointestinal disorders, but also as a
vehicle for drug synthesis and delivery to the intestine. First,
targeted delivery of drug to the gastrointestinal tract could permit
lower drug doses relative to systemic administration as well as
facilitate more direct interactions with the mucosal immune
system. Second, genetically modified yeast would be a less
expensive alternative to many proposed delivery mechanisms,
such as nanoparticles and liposomes, as yeast can be economically
produced on a large, industrial scale. Indeed, S. cerevisiae is
already used to produce such compounds as insulin, hepatitis B
surface antigen, granulocyte macrophage colony stimulating factor
(GM-CSF), and platelet derived growth factor (reviewed in [12]).
S. boulardii also has several advantages relative to other live
microorganisms proposed as drug delivery vehicles. As a
eukaryotic organism capable of expressing complex, glycosylated
antigens, S. boulardii can potentially express a much wider array
of compounds than probiotic bacteria. Also, S. boulardii shows
increased resistance to higher temperatures and low pH relative to
conventional laboratory strains of S. cerevisiae [13,14], which
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could translate to an increased ability of S. boulardii to survive
transit through the intestine. Furthermore, S. boulardii is not a
natural colonizer of the gastrointestinal tract in humans or mice
[15–18], which would allow for accurate drug dosing given reliable
clearance of S. boulardii from the intestine.
Although transformation of DNA into S. boulardii has been
reported to be less efficient than transformation of DNA into S.
cerevisiae [19], various methods of transformation have recently
been evaluated in S. boulardii [20]. Several studies have reported
successful transformation of DNA and production of recombinant
protein in S. boulardii [13,19,21–23]; however, feasibility of this
application is currently limited because prototrophic, wild type
(WT) S. boulardii can be transformed and selected only with
antibiotic resistance markers. Clinical use of these transformed
yeast on a large scale would thus carry risk of transferring
antibiotic resistance markers to the microbiota. A common
alternative to antibiotic selection of transformed yeast is the use
of auxotrophic mutants. Auxotrophic yeast lack enzymes critical
for the synthesis of essential amino acids or pyrimidines and can
grow in selective media only if they are transformed with a plasmid
encoding the required enzyme. Unfortunately, the only existing S.
boulardii auxotroph is unavailable for use in the United States
[22]. Thus there remains a need to generate an auxotrophic strain
of S. boulardii that can be easily manipulated without the use of
antibiotic resistance markers. This auxotrophic strain would also
need to produce recombinant protein during transit through the
gut despite the harsh digestive conditions and lack of selective
pressure. Such an auxotrophic strain would make S. boulardii a
much safer and more efficient vehicle to express and deliver
recombinant proteins to treat gastrointestinal disorders.
To develop a strain of S. boulardii that can be transformed
without antibiotic selection markers, we used a UV mutagenesis
approach and selected for auxotrophic mutants that lack a
functional orotidine 59-phosphate decarboxylase (Ura3), encoded
by the URA3 gene. The Ura3 enzyme decarboxylates orotidine
monophosphate (OMP) to form uridine monophosphate (UMP) in
the de novo synthesis pathway of pyrimidines. The ura32
auxotrophic yeast generated are unable to grow on media lacking
uracil, allowing for positive selection of ura32 mutant yeast
transformed with a URA3 plasmid on media lacking uracil. In
addition, Ura3 converts the compound 5-fluoroorotic acid (5-
FOA) to the toxin 5-fluorouracil, inducing cellular death of
URA3+ yeast plated on media containing 5-FOA and allowing for
easy identification of ura32 colonies.
Here we employed UV mutagenesis and 5-FOA screening to
generate three S. boulardii ura32 auxotrophic mutants. These
mutants can be transformed and selected without the use of
antibiotics. Furthermore, these mutants maintain the resistance to
bile acid and low pH that is characteristic of WT S. boulardii and
are taken up into immune tissues of the murine gastrointestinal
tract at a frequency similar to that of WT S. boulardii. These
mutant yeast also continue to express functional recombinant
protein after passage through the intestine and uptake into
immune tissues. In sum, we have developed S. boulardii strains
that could be adapted for use in the synthesis and delivery of drug
to the gastrointestinal tract.
Materials and Methods
Chemicals and Plasmids
All chemicals were obtained from Sigma, U. S. Biological Corp.
or Fisher Scientific unless otherwise noted, and all media were
prepared according to standard procedures [24]. All DNA
manipulations were performed according to standard methods
[25]. To construct the plasmids used in transformation of S.
boulardii mutants, the constitutive yeast promoter TEF1 from the
p427 plasmid (Dualsystems Biotech AG) was subcloned into
pRS426 [26], a 2m plasmid containing the S. cerevisiae URA3
sequence. The coding sequence of GFP was then subcloned into
the pRS426 plasmid under the TEF1 promoter.
Yeast Strains
Table 1 lists all yeast strains used, their auxotrophic markers,
and sources. WT S. boulardii (Ultra Levure, American Type
Culture Collection Number: MYA-797) was used for all muta-
genesis experiments. UV sensitive S. cerevisiae rad1 (SND 713)
[27] was used as a positive control in UV irradiation experiments.
S. cerevisiae RAD1 (SND 711) [27] is a wild type strain isogenic to
S. cerevisiae rad1 and was used for comparison in generating UV
survival curves. S. cerevisiae RM11-1a (GCY 2860), a wild type
haploid strain [28], was used in pH and bile acid testing. S.
cerevisiae W303, a well characterized laboratory haploid strain
(http://yeastgenome.org/), was used in pH, bile acid, and
anaerobic testing. S. cerevisiae YH990, a diploid strain, was used
for comparison in survival curve generation as well as pH, bile
acid, and anaerobic testing [29].
Survival Curve Generation
All media used for yeast growth were prepared according to
standard procedures [24]. Overnight YPD (1% yeast extract, 2%
peptone, 2% glucose/dextrose in distilled water) cultures of WT S.
boulardii and three S. cerevisiae strains (WT diploid, rad1, and
RAD1) were resuspended in 20 mL distilled water at a concen-
tration of 107 cells/mL. Diluted cells were then placed in a sterile
plastic petri dish 14 cm below the UV bulb of an Eppendorf UV
Stratalinker. Cells were exposed to UV irradiation with the lid
removed, with 500 mL of cells extracted at increments of 0 mJ,
5,000 mJ, 10,000 mJ, 15,000 mJ, 20,000 mJ, 22,500 mJ, 25,000 mJ,
30,000 mJ, and 50,000 mJ. Irradiated cells were serially diluted and
plated onto YPD media (2% agar, 1% yeast extract, 2% peptone,
2% glucose/dextrose in distilled water). Plates were covered in
aluminum foil to prevent photo-reactivation, and colony forming
units (CFU) were counted after 3–5 days incubation at 30uC.
Screening of UV Irradiated Cells
WT S. boulardii was prepared and irradiated as for generation
of survival curves with S. cerevisiae rad1 used as a control. Cells
were given doses of UV irradiation corresponding to approxi-
mately 50% WT S. boulardii survival (20,000–22,500 mJ) and
plated onto media containing 5-fluoroorotic acid (5-FOA) to select
for cells lacking a functional URA3 gene [30,31]. Colonies
resistant to 5-FOA were screened by multiple restreaking onto new
plates containing 5-FOA and plates lacking uracil as well as by
assessing growth in liquid media lacking uracil.
Confirmation of URA3 mutations
The primers URA3_Fwd (CCTGCAGGAAACGAAGAT-
AAATCATGTCGAAAGCTACATA) and URA3_Rev (CATT-
TACTTATAATACAGTTTTTTAGTTTTGCTGGCCGCA)
were used to PCR amplify the 804 bp URA3 coding region of the
S. boulardii mutants. PCR products were purified using the PCR
Purification Kit (Qiagen) and submitted to Beckman Coulter
Genomics for sequencing.
pH and Bile Acid Testing
WT S. boulardii; S. boulardii ura32 Mutants 1, 2, and 3; and S.
cerevisiae laboratory haploid (W303), diploid (YH990), and WT
Genetic Engineering of a Saccharomyces boulardii Mutant
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haploid (Rm11-1a) strains were grown overnight in YPD. Cells
(56107) were then resuspended in 500 mL YPD (approximately
pH 6); YPD adjusted to pH 2, 4, or 8 via addition of either 12 N
HCL or NaOH; complete media containing 0.3% OxGall (US
Biologicals); or media lacking uracil. For each dilution, 100 mL
was aliquoted in duplicate in 96 well plates (107 cells per well), and
optical density 600 (OD600) readings were taken over 24 hour
incubation at 37uC using a Bio Tek Instruments ELx 808 Ultra
Microplate Reader to assess growth.
Anaerobic Testing
WT S. boulardii; S. boulardii ura32 Mutants 1, 2, and 3; and S.
cerevisiae laboratory haploid (W303), diploid (YH990), and WT
haploid (Rm11-1a) strains were grown overnight in YPD. Yeast
were diluted to 56107 cells/mL in fresh YPD and incubated in a
vinyl anaerobic chamber (Type B; Coy Laboratory Products)
maintained at 37uC. The atmosphere of the chamber was filled
with an anaerobic gas mix comprised of 85% nitrogen, 10%
hydrogen and 5% carbon dioxide, and was set up and operated as
previously described [32]. One milliliter samples were taken over
24 hours to measure OD600 values. Samples were also taken at 12
and 24 hours for CFU counts.
Yeast Transformation
All yeast were transformed using standard electroporation [33]
and LiOAc [24] protocols. Briefly, for LiOAc transformation,
overnight cultures were diluted to 26106 cells/mL in fresh YPD
and incubated at 30uC until reaching a concentration of 107cells/
mL. Cells were then washed in sterile water and TE/LiOAc and
combined with plasmid DNA, carrier DNA, and PEG/TE/
LiOAc and agitated for 30 minutes at 30uC. DMSO was then
added and cells were heat shocked at 42uC for 15 minutes,
washed, and plated onto selective media. For electroporation, cells
were grown overnight to saturation, diluted to an OD600 of 0.2
and incubated until reaching an OD600 of 1.6. Cells were washed
with ice cold water and buffer containing 1 M sorbitol and 1 mM
CaCl2. Cells were resuspended in 100 mM LiOAc/10 mM DTT
and agitated for 30 min at 30uC. Pelleted cells were then washed
and resuspended in buffer containing 1 M sorbitol and 1 mM
CaCl2. A 400 mL volume of cells was combined with DNA, then
electroporated using a BioRad micropulser. Cells were then
transferred to a 1:1 mixture of YPD and 1 M sorbitol and
incubated one hour at 30uC with agitation. Cells were plated onto
media containing 1 M sorbitol.
Analysis of GFP Fluorescence
Images of untransformed yeast and yeast transformed with a
URA3 plasmid encoding GFP were collected using an Olympus
IX80. Flow cytometry was performed by resuspending cells in
FACS buffer (sterile PBS and 0.5% FBS) and analyzing them using
a BD LSR II flow cytometer and B530/30 filter.
Isolation of Viable Yeast from Murine Peyer’s Patches
All animal experiments were conducted strictly in adherence to
the guidelines and recommendations in the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Experiments were approved by the Emory University Institutional
Animal Care and Use Committee (Protocol number: DAR-
2002655-021817BN), and euthanasia was performed using CO2.
WT female C57BL/6J mice aged 6–8 weeks were gavaged
108 CFU of either WT S. boulardii, S. cerevisiae laboratory
haploid, or S. boulardii Mutant 2. Peyer’s patches from each
mouse were harvested four hours post gavage, cell strained, and
plated onto yeast media to detect viable colonies. YPD plates were
used in plating of untransformed yeast and plates lacking uracil
were used to select S. cerevisiae laboratory haploid and S.
boulardii Mutant 2 transformed with a URA3 plasmid. CFU were
counted after 2–4 days incubation at 30uC. The sample size
needed to determine a statistically significant difference was
calculated using Lehr’s formula n = 2(1.96+0.8416)2/(d/s)2 where
d is the smallest meaningful difference in means and s is the
standard deviation of the observations in each group, assuming a
power of 80% and a significance of 5% [34].
Results
Numerous studies have characterized superior growth of S.
boulardii relative to S. cerevisiae strains [13,14]. In order to test
growth of S. boulardii (ATCC MYA-797) compared to the S.
cerevisiae strains used in this study (Table 1), yeast were incubated
for 24 hours at either 30uC, the optimal growth temperature for
most S. cerevisiae strains [20], or 37uC, normal human body
temperature. Growth of S. boulardii was compared to three strains
of S. cerevisiae. W303 was selected due its frequent use as an S.
cerevisiae laboratory haploid strain. RM11-1a, an S. cerevisiae
WT haploid strain that has been more recently isolated and which
carries a lower rate of age related mutations relative to other S.
cerevisiae strains, was used as a natural isolate comparison to S.
boulardii [28]. Finally, S. cerevisiae YH990, a diploid, was used to
compare growth of S. boulardii to that of another diploid yeast
strain.
As shown in Figure 1, S. boulardii shows a faster rate of growth
and higher saturation point at both 37uC and 30uC relative to all
three S. cerevisiae strains tested (laboratory haploid, WT haploid,
and diploid) in normal rich media (YPD). Although S. boulardii
actually reaches a higher saturation point at 30uC versus 37uC, its
superior growth at 37uC relative to S. cerevisiae indicates that S.
Table 1. Tinoofpression by aromyces boulardii Auxotrophicine ii to create an optimal probiotic drug delivery system.
Strain Designation Description Source
S. boulardii WT S. boulardii MYA-797 American Type Culture Collection
S. cerevisiae SND 713 S. cerevisiae rad1 rad1::kanMX; spore of hNDP223 [27]
S. cerevisiae SND 711 S. cerevisiae RAD1 WT spore of hNDP223 [27]
S. cerevisiae W303 S. cerevisiae laboratory haploid MATa ura3D leu2D trp1D his3D http://www.yeastgenome.org/
S. cerevisiae YH990 S. cerevisiae diploid 2n a/a by YEpHO-LEU2 of E134 [29]
S. cerevisiae RM11-1a
(GCY 2860)
S. cerevisiae wild type haploid MATa ho::loxP lys2D0 ura3D0 Generated by transient Cre expression to eliminate G418
resistance marker in strain UCC1159 [28]
doi:10.1371/journal.pone.0112660.t001
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boulardii is more likely to show better growth at body temperature
than S. cerevisiae.
Diploid S. boulardii Require High Doses of UV Irradiation
to Achieve 50% Cell Survival
UV mutagenesis coupled with 5-FOA resistance was used to
screen for ura32 S. boulardii mutants. Previous UV mutagenesis
studies have used high UV doses, resulting in only 10–20%
survival, to screen for auxotrophic mutants [22,35]. Most of these
studies targeted haploid S. cerevisiae strains; however, there has
been only one report of tetrad formation and isolation of haploid
S. boulardii cells [13]. Indeed, attempts in the present study to
induce S. boulardii sporulation were unsuccessful. Higher doses of
UV irradiation may thus be necessary to increase the likelihood of
inducing homozygous mutations in both copies of S. boulardii
URA3. However, in light of potential future in vivo applications,
lower doses of irradiation would be optimal to avoid mutating
genes related to S. boulardii’s superior growth and immunomod-
ulatory characteristics. A 50% survival dose of UV irradiation was
therefore chosen to screen for ura32 S. boulardii mutants.
To determine the UV dose necessary to kill 50% of S. boulardii
cells, WT S. boulardii as well as S. cerevisiae strains laboratory
haploid, diploid, RAD1, and UV sensitive rad1 cells were exposed
to UV irradiation (Fig. 2). As expected, the S. cerevisiae rad1
mutant was killed even with low doses (5,000 mJ) of UV
irradiation. Comparing percent survival versus UV dose shows
that, as expected, higher doses of UV irradiation are needed to kill
WT S. boulardii and S. cerevisiae diploid cells relative to S.
cerevisiae haploid RAD1 cells. The UV dose corresponding to
approximately 50% WT S. boulardii survival was determined to
be 20,000–22,500 mJ and was used for subsequent screening for S.
boulardii ura32 mutants.
Isolation of Three S. boulardii Mutants Unable to Grow
Without Uracil
Approximately 2.26108 WT S. boulardii cells were irradiated at
a 50% survival dose (20,000–22,500 mJ) and plated onto media
containing 5-FOA (Fig. 3A). Of these irradiated cells, approxi-
mately 2,200 were 5-FOA resistant. Eighty of these 5-FOA
resistant colonies were further screened to confirm their ability to
grow on plates containing 5-FOA and their inability to grow on
plates or in liquid media lacking uracil (Fig. 3B, C). As expected,
WT S. boulardii can grow on YPD plates or plates lacking uracil
but does not grow on plates containing 5-FOA. In contrast, S.
boulardii Mutants 1, 2, and 3 (M1, M2, and M3) show a pattern of
growth similar to that of the laboratory haploid ura32 S.
cerevisiae strain, with the ability to grow on YPD plates or plates
containing 5-FOA, but not on plates lacking uracil. Although the
vast majority of colonies originally isolated from 5-FOA plates
showed a high rate of reversion to a URA3+ phenotype
(approximately 1–2% reversion), S. boulardii Mutants 1–3 showed
a relatively low rate of reversion (Fig. 3D) comparable to that seen
for a commonly used ura32 laboratory haploid S. cerevisiae
strain. Indeed, S. boulardii M2 showed no detectable reversion.
Sequence analysis of the URA3 open reading frame in S.
boulardii Mutants 1–3 revealed single amino acid substitutions
located outside of specific functional domains (Fig. 4A). M1 and
M3 both contained an A160S amino acid substitution, while M2
contained an S81F amino acid substitution. Although simulta-
neous mutation of both copies of URA3 in the diploid S. boulardii
is likely to be an extremely rare event, selective pressure due to the
presence of 5-FOA could have facilitated duplication of mutated
URA3. Structural modeling of the S. cerevisiae Ura3 protein (PDB
ID: 1DQX [36]) (Fig. 4B, C) reveals that residue serine 81 is
located within an a-helix. A change from serine (Fig. 4C) to the
larger phenylalanine (Fig. 4D) at residue 81 could cause a steric
clash with surrounding amino acids including phenylalanine 86
and leucine 87 on the opposing b strand, likely impairing proper
protein folding and catalytic function. The reason for lack of Ura3
function in M1 and M3 is less clear than for M2. Residue 160 is
Figure 1. S. boulardii Shows Enhanced Growth Relative to S.
cerevisiae at Both 306C and 376C. Yeast were grown overnight in
YPD and diluted to 107 cells per well in a 96 well plate. OD600 readings
over 24 hours incubation at 37uC or 30uC indicate relative growth of
wild type S. boulardii (WT S.b.), S. cerevisiae laboratory haploid (S.c. lab
haploid), S. cerevisiae wild type haploid (S.c. WT haploid), and S.
cerevisiae diploid (S.c. diploid). Lines represent the mean of duplicate
experiments, with error bars depicting plus the standard error of the
mean (SEM). Shading highlights growth of yeast strains relative to
growth of W T S. boulardii at 37uC.
doi:10.1371/journal.pone.0112660.g001
Figure 2. Fifty Percent of S. boulardii Cells Survive at 20,000–
22,500 mJ UV Irradiation. Wild type (WT) S. boulardii and S. cerevisiae
diploid, haploid RAD1, and haploid rad1 were exposed to various doses
of UV irradiation. Percent survival (CFU as a percentage of total cells
irradiated and plated) was plotted at each dose (mean of n = 2 per strain
per UV dose, with error bars depicting plus the standard error of the
mean) to identify the dose of UV irradiation corresponding to 50%
survival of WT S. boulardii cells. Greater than 100% survival was likely
reached at some low UV doses due to cellular replication after
irradiation.
doi:10.1371/journal.pone.0112660.g002
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located approximately 10 A˚ from the catalytic site and outside of
any a-helices or b-pleated sheets (Fig. 4B, E–F). Although residue
160 is conserved in Homo sapiens, Mus musculus, Danio rerio, and
WT S. boulardii (Fig. 4A) as alanine, the S. cerevisiae +D4 Ura3
protein contains a serine at the homologous position [37].
Furthermore, the crystal structure of Ura3 from S. cerevisiae has
been solved with an A160S substitution (Fig. 4B) (PDB ID: 1DQX
[36]). These data suggests that mutations outside the open reading
frame, such as in promoter or enhancer regions, might instead
account for lack of Ura3 function in M1 and M3.
S. boulardii Mutants are Resistant to Low pH and Bile
Acid In Vitro
As in previous studies [13,14], S. boulardii shows enhanced
growth relative to S. cerevisiae strains in YPD as well as in media
at pH 4, pH 8, and containing bile salts (0.3% OxGall) (Fig. 5 A–
D). In order to determine if S. boulardii Mutants 1–3 retained the
characteristic ability of WT S. boulardii to withstand pH changes
and bile acid, WT and mutant S. boulardii were grown in pH-
adjusted media for 24 hours (Fig. 5A, E–G). All three S. boulardii
mutants grow similarly in media at pH 4, pH 8, and 0.3% OxGall
and reach a similar optical density (OD600) at saturation. Notably,
growth of all three S. boulardii mutants in YPD is decreased
relative to WT S. boulardii (OD600 of approximately 0.6 at
saturation for S. boulardii mutants versus over 1.0 for WT S.
boulardii) (compare Fig. 5A to Fig. 5E–G). However, growth of S.
boulardii mutants in media containing 0.3% OxGall or media at
pH 4 is decreased only slightly relative to mutant growth in YPD.
Furthermore, S. boulardii mutants appear less affected by media at
pH 8 relative to S. cerevisiae laboratory haploid and diploid cells.
Although the S. boulardii mutant growth rate at pH 8 is decreased
relative to growth in YPD, OD600 at saturation in media at pH 8
almost reaches that seen with mutant growth in YPD. In contrast,
growth of S. cerevisiae laboratory haploid and diploid strains at
pH 8 never reaches that seen in YPD. These results indicate that
while the saturation point for growth of S. boulardii mutants is
decreased relative to WT S. boulardii, pathways influencing pH
and bile acid resistance have been maintained.
S. boulardii Mutants Show Increased Growth in Anaerobic
Conditions
Given the ability of WT S. boulardii to grow in the anaerobic
conditions of the gastrointestinal system, WT S. boulardii and
Mutants 1–3 were incubated in anaerobic conditions for 24 hours
(Fig. 6). OD600 readings show that both WT and mutant S.
boulardii grow more quickly and to a higher saturation point than
the tested S. cerevisiae strains (lab haploid and diploid) (Fig. 6A).
Similarly, CFU counts of samples taken at 12 and 24 hours
incubation in anaerobic conditions show the highest number of
viable cells for Mutants 1–3 followed by WT S. boulardii, with the
lowest cell numbers for S. cerevisiae lab haploid and diploid
(Fig. 6B).
Figure 3. Isolation of Three S. boulardii Mutants Unable to Grow Without Uracil. (A) Flow diagram depicting the number of irradiated wild
type (WT) S. boulardii cells, screened 5-FOA resistant colonies, and final number of S. boulardii ura32 mutants obtained. (B) Growth of WT S. boulardii,
S. boulardii Mutants 1–3 (M1, M2, M3), and ura32 S. cerevisiae laboratory haploid was assessed by serial dilution and spotting on YPD, uracil2, and 5-
FOA plates. (C) Growth of S. boulardii Mutants 1–3 relative to WT S. boulardii and ura32 S. cerevisiae laboratory haploid at 37uC in liquid media lacking
uracil. Lines represent the mean of duplicate experiments for each strain, with error bars depicting plus and minus the standard error of the mean
(SEM). (D) Number of CFU able to grow on plates lacking uracil per 109 plated cells. Each bar depicts the mean of duplicate experiments with error
bars depicting plus the SEM.
doi:10.1371/journal.pone.0112660.g003
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S. boulardii Mutants Can Be Transformed and Express
Functional GFP
In order to determine whether the S. boulardii mutants can be
successfully transformed and express heterologous protein, S.
boulardii Mutants 1–3 were transformed with a URA3 plasmid
encoding GFP. Fluorescence microscopy reveals GFP fluorescence
in transformed S. boulardii mutants and S. cerevisiae laboratory
haploid cells, but no background fluorescence in untransformed
yeast (Fig. 7A). In addition, flow cytometry analysis shows a high
percentage of GFP-expressing cells in transformed S. cerevisiae
(44% v. 0.63% for transformed and untransformed yeast,
respectively) and S. boulardii Mutant 2 (61.2% v. 0.68% for
transformed and untransformed yeast, respectively) (Fig. 7B).
These results demonstrate that S. boulardii mutants can express
GFP as efficiently as the well characterized S. cerevisiae laboratory
haploid strain.
To test the ability of S. boulardii mutants to maintain plasmid
and heterologous protein expression without selective pressure, as
will occur in the gastrointestinal system, transformed yeast were
incubated in YPD for 4 or 24 hours and subsequently tested for
GFP expression. As shown by flow cytometry, transformed S.
cerevisiae and S. boulardii Mutants 1–3 incubated in YPD for 4 or
24 hours maintained a high percentage of GFP-expressing cells
comparable to that of yeast maintained in selective media lacking
uracil (Fig. 7C). GFP positive S. boulardii mutant cells also
maintained comparable median fluorescence intensity after
incubation in non selective YPD media, indicating that on average
not only the number of cells but also GFP expression per cell was
maintained over 24 hours without selective pressure.
Viable Transformed S. boulardii Mutant 2 Expressing GFP
Can Be Isolated from Murine Peyer’s Patches
Use of transformed mutant S. boulardii for delivery of
recombinant protein to the intestine depends not only on the
ability to maintain plasmid without selection but also on the ability
to survive passage through the gastrointestinal tract. Furthermore,
in the case of cytokine delivery, the ability to contact immune
tissues of the small intestine will be critical in helping to induce
anti-inflammatory responses. Peyer’s patches are major sites of
antigen sampling from the small intestine lumen as well as key sites
of immune response induction and development [38]. Thus,
uptake of transformed yeast into Peyer’s patches would indicate
the ability of yeast not only to survive passage through the
gastrointestinal tract but also to contact tissues responsible for
mediating immune responses. As all three S. boulardii mutants
showed similar resistance in vitro to low pH and bile acid
(Fig. 5E–G) and to anaerobic conditions (Fig. 6), S. boulardii
Figure 4. S. boulardii ura32 Mutants Contain Single Amino Acid Changes Within the Ura3 Protein. (A) Schematic showing the domain
structure of Ura3 protein in regions surrounding the amino acid changes in S. boulardii ura32 mutants. Ura3 substrate binding sites are shown in gray
with arrows above (amino acids 37, 59–61, 91–100, 217, 235) and the active site as a black line with asterisk above (amino acid 93). The altered amino
acid sites in the S. boulardii mutants are shown as purple (S81F in M2) and yellow (A160S in M1 and M3) lines with the changes indicated below.
Homologous regions including the altered amino acids and the 20 surrounding residues in Homo sapiens, Mus musculus, Danio rerio, Drosophila
melanogaster, Saccharomyces cerevisiae, and WT S. boulardii are depicted to show conservation of these residues. (B) Ribbon depiction of the S.
cerevisiae Ura3 homodimer bound to the proposed transition state analog 6-hydroxyuridine 59-phosphate (PDB ID: 1DQX) [36]. The S. boulardii
mutant single amino acid changes are noted in yellow (A160S in M1 and M3) and purple (S81F in M2). (C) Enlarged view showing the wild type serine
residue at position 81. (D) Enlarged view showing the amino acid change to phenylalanine at position 81 in S. boulardii Mutant 2. (E) Enlarged view
showing the wild type alanine residue at position 160. (F) Enlarged view showing the amino acid change to serine at position 160 in S. boulardii
Mutants 1 and 3.
doi:10.1371/journal.pone.0112660.g004
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Mutant 2 was used for in vivo experiments in mice as this mutant
has no detectable reversion to a URA3+ phenotype (Fig. 3D).
To test for survival of S. boulardii Mutant 2 in the
gastrointestinal tract, C57BL/6 mice were gavaged with water
(Naı¨ve), 108 CFU untransformed WT S. boulardii, or S. boulardii
Mutant 2 or 108 CFU S. cerevisiae laboratory haploid trans-
formed with the URA3 GFP plasmid (Fig. 8A). Peyer’s patches
were harvested four hours post gavage, cell strained, and plated
onto selective media lacking uracil. Peyer’s patches from naı¨ve
mice were also plated onto YPD to check for the presence of
contaminating yeast unable to grow in the absence of uracil. After
2–5 days incubation at 30uC, plates showed no viable yeast
Figure 5. S. boulardii ura32 Mutants are Resistant to In Vitro Intestine-Like Conditions. Yeast were grown overnight in YPD and diluted to
107 cells per well in a 96 well plate. OD600 readings were taken over 24 hours incubation at 37uC. Graphs depict growth of yeast strains at pH 2, pH 4,
pH 8, 0.3% OxGall, and YPD (approximately pH 6). Yeast strains include wild type (WT) S. boulardii (A); S. cerevisiae strains laboratory haploid (B),
diploid (C), and wild type haploid (D); and S. boulardii M1 (E), M2 (F), and M3 (G). This analysis shows that S. boulardii mutants maintain resistance to
pH 4 and pH 8 as well as to 0.3% OxGall whereas S. cerevisiae strains laboratory haploid and diploid are sensitive to these conditions.
doi:10.1371/journal.pone.0112660.g005
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detected in Peyer’s patches of naı¨ve mice (Fig. 8B, Naı¨ve), few to
no colonies of transformed S. cerevisiae (Fig. 8B, S.c. GFP), and
many viable colonies for both transformed S. boulardii Mutant 2
(M2 GFP) and untransformed WT S. boulardii (WT S.b.)
(Fig. 8B). These results are quantitated in Figure 8C. Viable
transformed S. boulardii Mutant 2 furthermore showed a high
percentage of GFP+ cells, as determined by flow cytometry
(Fig. 8D). This result indicates that transformed S. boulardii
Mutant 2 is capable of maintaining heterologous protein
expression despite the lack of selective pressure and harsh growth
conditions within the gastrointestinal tract.
Notably, there was a high degree of variability in number of
viable CFU harvested per mouse (Fig. 8C), especially for the WT
S. boulardii and S. boulardii Mutant 2 groups. As observed
previously for recovery of viable WT S. boulardii versus S.
cerevisiae S1278b and BY3 strains from murine Peyer’s patches
[13], this variability prevented the trend of increased viable WT S.
boulardii and S. boulardii Mutant 2 versus S. cerevisiae from
reaching statistical significance (power calculations indicate a
sample size of greater than 200 mice is needed to determine a
statistically significance between the Mutant 2 and S. cerevisiae
groups, given an alpha of 0.05 and an expected significant
difference of 5 CFU). Such variability could be due to numerous
factors, including differences in feeding prior to oral gavage,
differences in digestion and gastrointestinal motility, or margins of
error in Peyer’s patch dissection.
Discussion and Conclusions
A major requirement for the development of S. boulardii as a
viable drug delivery system is the development of strains that can
maintain protein expression in the harsh digestive conditions of the
gastrointestinal tract. Here, we employed UV mutagenesis and 5-
FOA screening to generate three S. boulardii auxotrophic mutant
strains that can be genetically modified and transformed without
reliance on antibiotic resistance markers. Critically, S. boulardii
Mutants 1–3 can be transformed with URA3 plasmids and express
functional recombinant protein as demonstrated by GFP fluores-
cence (Fig. 7A–B). S. boulardii Mutants 1–3 maintained expres-
sion of recombinant protein for 24 hours after removal of selective
pressure (Fig. 7C), a feature that will be especially important in the
context of in vivo drug delivery. The ability of transformed
mutants to continue producing GFP even after 24 hours without
selective pressure suggests their potential to express and deliver
recombinant proteins during transit through the gastrointestinal
tract.
S. boulardii has previously been used successfully to produce the
mammalian anti-inflammatory cytokine interleukin 10 (IL-10)
[20]. This study not only confirmed the ability of WT S. boulardii
to successfully produce properly folded IL-10 as demonstrated by
ELISA, but also showed in vivo functionality of this secreted
cytokine. Oral gavage of transformed S. boulardii expressing IL-10
improved ulceration scores of mice in the dextran sodium sulfate
(DSS) colitis model, although there was no difference in colonic
thickening or histological score compared to controls. While this
study provides proof of principle for expression of a therapeutically
Figure 6. S. boulardii ura32 Mutants Grow in In Vitro Anaerobic Conditions. (A) Wild type (WT) S. boulardii; S. cerevisiae strains laboratory
haploid, diploid, and wild type haploid; and S. boulardii M1, M2, and M3 were grown overnight in YPD and diluted to 56107 cells/mL in fresh YPD.
OD600 readings were taken over 24 hours incubation in a vinyl anaerobic chamber maintained at 37uC. (B) Number of colony forming units (CFU) per
mL for each yeast strain after 12 and 24 hours incubation in the vinyl anaerobic chamber. This analysis shows that WT S. boulardii and particularly S.
boulardii Mutants 1–3 show superior growth in anaerobic conditions relative to S. cerevisiae strains.
doi:10.1371/journal.pone.0112660.g006
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relevant recombinant protein by S. boulardii, transformation in
this study was dependent on the presence of aminoglycoside
resistance markers and growth in media supplemented with
antibiotic. Our use of ura32 auxotrophic mutant strains of S.
boulardii in the present study allowed for selection of transfor-
mants simply using media lacking uracil, obviating the need for
antibiotic resistance markers.
A goal is to genetically engineer S. boulardii strains to produce
uracil auxotrophy without additional mutations that could impact
desirable growth properties of this clinically used probiotic strain.
Although a moderate dose of UV irradiation was selected in order
to mutate URA3 while limiting the number of additional
mutations, genes other than URA3 have likely been affected in
S. boulardii Mutants 1–3. Indeed, overall growth of the three
ura32 S. boulardii mutants is reduced relative to that of WT S.
boulardii (Fig. 5). The exact mutations responsible for this reduced
growth were not determined. Generation of a ura32 S. boulardii
strain in future studies using a targeted approach would allow for
creation of an auxotrophic mutant while maintaining pathways
responsible for the superior growth rate and immunomodulatory
properties of WT S. boulardii.
Despite a modest impact on growth rate, the three ura32 S.
boulardii mutants generated in this study show resistance in vitro
to a wide range of pH, bile acid, and anaerobic conditions similar
to that of the gastrointestinal tract (Fig. 5, 6). Growth of Mutants
1–3 in anaerobic conditions is in fact higher than for WT S.
Figure 7. S. boulardiiMutants Express Functional GFP. (A) Bright field and fluorescent images of ura32 S. cerevisiae laboratory haploid (S.c.) and
S. boulardii Mutant 2 (M2) either untransformed (Control) or transformed (+GFP) with a URA3 plasmid containing GFP. The GFP fluorescence is
detected in the FITC channel. Corresponding differential interference contrast (DIC) images are also shown. Scale bars show 10 mm. (B) Representative
flow cytometry plots of forward-scattered light (FSC) versus GFP fluorescence for untransformed (Control) and transformed (+GFP) S. cerevisiae
laboratory haploid (S.c. lab haploid) and S. boulardii Mutant 2 (M2) showing the percent of GFP positive cells in each population (n = 2 per strain).
Transformed yeast were maintained in media lacking uracil prior to analysis. (C) Retention of URA3 plasmid and GFP expression was tested by
comparing the percent of GFP positive cells of untransformed yeast (Control) relative to transformed yeast cultured in either selective media lacking
uracil (URA2Glu), YPD (non selective media) for 4 hours (YPD 4 hr), or YPD for 24 hours (YPD 24 hr). Yeast strains analyzed include untransformed and
transformed ura32 S. cerevisiae laboratory haploid (S.c.) and S. boulardii Mutants 1–3 (M1, M2, M3). Median fluorescent intensity (MFI) of GFP positive
cells in each population is also depicted, indicating there is no visible decrease in average GFP expression per cell after incubation in YPD for 4 or
24 hours. Bars depict the mean of two samples per strain per incubation condition.
doi:10.1371/journal.pone.0112660.g007
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boulardii and S. cerevisiae (Fig. 6). Although growth of S.
boulardii Mutants 1–3 in YPD is reduced relative to WT S.
boulardii in aerobic conditions, their growth in low pH and bile
acid relative to growth in normal YPD media is maintained.
Resistance to low pH is a key feature of S. boulardii, distinguishing
it from even closely related S. cerevisiae strains. Consistent with
these findings, previous studies provide evidence that WT S.
boulardii shows resistance to low pH [39]. Maintenance of
resistance to low pH and anaerobic conditions could allow S.
boulardii Mutants 1–3 not only to synthesize therapeutic proteins
but also to serve as protective capsules for those proteins during
transit through the gut. Use of these auxotrophic mutants for
protein synthesis and packaging would decrease cost of oral drug
development by eliminating the expensive steps of purifying and
packaging proteins into capsules such as liposomes or nanopar-
ticles.
To assess the potential for S. boulardii auxotrophic mutants to
serve as drug delivery vehicles, we tested their ability to maintain
production of recombinant protein in vivo. For these oral gavage
experiments, we selected S. boulardii Mutant 2, which showed
equal or superior resistance to low pH, bile acid, and anaerobic
conditions relative to the other mutants (Fig. 5, 6), comparable
production of GFP in vitro (Fig. 7A–C), and reversion to a URA3+
phenotype at a rate below the limit of detection (Fig. 3D). Viable
S. boulardii Mutant 2 was isolated within murine small intestine
Peyer’s patches at a frequency similar to that of WT S. boulardii
(Fig. 8C), indicating that in vivo survival through the gastrointes-
tinal tract and uptake into small intestine immune tissues is
maintained for this mutant and supporting the in vitro data
showing that this mutant is resistant to low pH and bile acid
(Fig. 5). High levels of GFP expression in transformed S. boulardii
Mutant 2 recovered from Peyer’s patches furthermore indicate
that this mutant is capable of delivering recombinant protein to
the gastrointestinal tract and its associated immune tissues
(Fig. 8D). In fact, our results in this experiment likely underesti-
mate the number of ura32 S. boulardii Mutant 2 cells entering the
Peyer’s patches as our assay was capable of detecting only viable
yeast; ura32 S. boulardii that entered as cellular fragments or that
were phagocytosed by antigen presenting cells within Peyer’s
patches could not be detected. The ability of ura32 S. boulardii to
be taken up into immune tissues makes it well suited for oral
delivery of immunomodulatory therapeutics. For example, ura32
S. boulardii could be used to express and deliver IL-10 to immune
tissues of the gastrointestinal tract and thus promote anti
inflammatory immune responses in the context of inflammatory
bowel disease.
In summary, the ura32 S. boulardii mutants generated in this
study possess all the characteristics needed for safe and efficient use
Figure 8. Viable Transformed S. boulardii Mutant 2 can be
Recovered from Gastrointestinal Immune Tissue. (A) Schematic
depicting oral gavage experiments. C57BL/6 mice were gavaged with
100 mL containing either water, 108 CFU wild type S. boulardii (WT S.b.),
108 CFU S. boulardii Mutant 2 (M2), or 108 CFU ura32 S. cerevisiae
laboratory haploid (S.c.). Peyer’s patches, sites of antigen sampling and
immune response generation in the gastrointestinal tract (reviewed in
[38]), were harvested 4 hours post gavage and plated to detect viable
CFU. (B) Images of typical plates from oral gavage experiments showing
recovery of viable yeast from Peyer’s patches. Samples from mice
gavaged with WT S. boulardii, S. boulardii Mutant 2 transformed with
URA3 plasmid, or S. cerevisiae laboratory haploid transformed with URA3
plasmid were plated on media lacking uracil. Samples from naı¨ve mice
were also plated on YPD media to detect any contaminating yeast
unable to grow without uracil. (C) CFU per mouse recovered from
Peyer’s patches of mice orally gavaged with water (Naı¨ve), WT S.
boulardii (WT S.b.), S. boulardii Mutant 2 (M2), or S. cerevisiae laboratory
haploid (S.c.) (n = 20 mice per group). Lines show the mean CFU per
mouse for each group. Two data points for S. boulardii Mutant 2 (87 and
110 CFU per mouse) are not depicted in order to allow better
visualization of other data points. The mean without the two high
points is 2.5 (shown in solid black line). The mean including the two
points is 12.1 (shown in dotted line). (D) Representative flow cytometry
plots of forward-scattered light (FSC) versus GFP fluorescence showing
the percent of GFP positive cells among untransformed S. boulardii
Mutant 2 (M2 control) and S. boulardii Mutant 2 that was transformed
with a URA3 plasmid encoding GFP (M2+GFP) and subsequently
recovered from murine Peyer’s patches (26 total transformed S.
boulardii M2 CFU recovered from Peyer’s patches were assessed by
flow cytometry).
doi:10.1371/journal.pone.0112660.g008
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as an oral drug delivery system. These mutants can be transformed
and selected using auxotrophic markers to avoid reliance on
antibiotic selection. Furthermore, they can express heterologous
protein to a similar level as a commonly used laboratory S.
cerevisiae strain, as demonstrated by comparable levels of GFP
fluorescence. These S. boulardii mutants also maintain high levels
of protein expression even after prolonged incubation in nonse-
lective media and uptake into the immune tissues of the murine
gastrointestinal tract. These newly generated S. boulardii auxo-
trophic mutants are therefore good candidates for further testing
as drug delivery vehicles for the treatment of gastrointestinal
disorders.
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